[ 1 ] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1): 11-30.
[2]
[ 2 ] Lin Y, Totsuka Y, He Y, et al. Epidemiology of esophageal cancer in Japan and China[J]. J Epidemiol, 2013, 23(4): 233-242.
[3]
[ 3 ] Cox JD, Stetz J, Pajak TF. Toxicit y criteria of the radiation therapy oncology group (RTOG) and the European orqanization for research and treatment of cancer (EORTC) [J]. Int J Radiat Oncol Biol Phys, 1995, 31(5): 1341-1346.
[ 5 ] Trott KR, Herrmann T, Kasper M. Target cells in radiation pneumopathy[J]. Int J Radiat Oncol Biol Phys, 2004, 58(2): 463-469.
[6]
[ 6 ] Molteni A, Wolfe LF, Ward WF, et al. Effect of an angiotensin Ⅱ receptor blocker and two angiotensin converting enzyme inhibitors on transforming growth factor-beta (TGF-beta) and alpha-actomyosin (alpha SMA), important mediators of radiation-induced pneumopathy and lung fibrosis[J]. Curr Pharm Des, 2007, 13(13): 1307-1316.
[7]
[ 7 ] Murray LA, Chen Q, Kramer MS, et al. TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P[J]. Int J Biochem Cell Biol, 2011, 43(1): 154-162.
[8]
[ 8 ] Hill RP, Zaidi A, Mahmood J, et al. Investigations into the role of inflammation in normal tissue response to irradiation[J]. Radiother Oncol, 2011, 101(1): 73-79.
Dang J, Li G, Lu X, et al. Analysis of related factors associated with radiation pneumonitis in patients with locally advanced non-small-cell lung cancer treated with three-dimensional conformal radiotherapy[J]. J Cancer Res Clin Oncol, 2010, 136(8): 1169-1178.
[11]
Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)[J]. Int J Radiat Oncol Biol Phys, 1999, 45(2): 323-329.
[12]
Tsujino K, Hirota S, Endo M, et al. Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer[J]. Int J Radiat Oncol Biol Phys, 2003, 55(1): 110-115.
[13]
Rodrigues G, Lock M, D’souza D, et al. Prediction of radiation pneumonitis by dose - volume histogram parameters in lung cancer: a systematic review[J]. Radiother Oncol, 2004, 71(2): 127-138.
Mccurdy M, Mcaleer MF, Wei W, et al. Induction and concurrent taxanes enhance both the pulmonary metabolic radiation response and the radiation pneumonitis response in patients with esophagus cancer[J]. Int J Radiat Oncol Biol Phys, 2010, 76(3): 816-823.
[16]
Kong FM, Hayman JA, Griffith KA, et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis[J]. Int J Radiat Oncol Biol Phys, 2006, 65(4): 1075-1086.
[17]
Asakura H, Hashimoto T, Zenda S, et al. Analysis of dose-volume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancer[J]. Radiother Oncol, 2010, 95(2): 240-244.
[18]
Marks LB, Spencer DP, Sherouse GW, et al. The role of three dimensional functional lung imaging in radiation treatment planning: the functional dose-volume histogram[J]. Int J Radiat Oncol Biol Phys, 1995, 33(1): 65-75.
